Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -17.26%4 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 939 Biotechnology companies, BeBetter Med ranks worse than 106496.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BeBetter Med's EBITDA for the
three
months ended in Mar. 2026 was ¥-52.77 Mil. BeBetter Med's Revenue for the
three
months ended in Mar. 2026 was ¥0.00 Mil. Therefore, BeBetter Med's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
BeBetter Med (SHSE:688759) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BeBetter Med EBITDA Margin % Related Terms
BeBetter Med EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BeBetter Med's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, BeBetter Med's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BeBetter Med's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeBetter Med (SHSE:688759) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BeBetter Med and its competitors. According to the industry distribution chart, BeBetter Med ranks #999999 out of 939 companies in the Biotechnology industry.
Is BeBetter Med's EBITDA Margin % too high?
BeBetter Med's current EBITDA Margin % is 0.00%. Based on the distribution chart, BeBetter Med ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #999999 out of 939 companies for EBITDA Margin %. This places BeBetter Med in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BeBetter Med and its competitors. BeBetter Med's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
